COMP <GO>
NAGE vs ABBV // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Niagen Bioscience Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: NAGE 5
— ABBV 7
■ METRIC PARITY
LAST: $2.50 (-1.57%) • MKT CAP: $197.8M
options-implied-move
—
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NAGE VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NAGE | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 64.30% | 70.20% | -5.90 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 16.80% | 29.00% | -12.20 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 12.2x | 33.3x | -21.10 | NAGE | /valuation <GO> |
| Free Cash Flow Yield | 6.83% | 3.47% | +3.36 | NAGE | /fcf-yield <GO> |
| Operating Margin | 12.60% | 24.60% | -12.00 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 13.40% | 6.90% | +6.50 | NAGE | /net-margins <GO> |
| Revenue Growth (YoY) | 29.90% | 8.60% | +21.30 | NAGE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.40 | 5.33 | -0.93 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.1 | 65.1 | -22.00 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 9.6x | 113.1x | -103.50 | NAGE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $197.8M | $513.86B | -$513.66B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NAGE REV | ABBV REV | NAGE GROSS % | ABBV GROSS % | NAGE FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $129.4M | $61.16B | 64.3% | 70.2% | $13.5M | $17.82B |
| FY 2024 | $99.6M | $56.33B | 61.8% | 70.0% | $12.1M | $17.83B |
| FY 2023 | $83.6M | $54.32B | — | — | $7.1M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NAGE // BETA —
ABBV // BETA 1.15